Questions: The History of Vaccination: From Cowpox to mRNA

Question 1

Edward Jenner's 1796 smallpox vaccination used a completely different approach from modern vaccine theory. What did Jenner do, and why did it work even without understanding the mechanism?

Model answer: Jenner observed that milkmaids who contracted cowpox (a mild disease) seemed protected against the much more dangerous smallpox. In 1796, he inoculated a boy with cowpox material and later exposed him to smallpox — the boy did not get smallpox. Jenner had no knowledge of viruses, the immune system, or antibodies. It worked because cowpox and smallpox viruses share antigens — surface proteins — and the immune system's response to cowpox created antibodies that cross-reacted with smallpox virus. Jenner's empirical success was centuries ahead of its mechanistic understanding.

The gap between Jenner's empirical discovery (1796) and mechanistic understanding of how vaccines work (immune system structure understood in the 20th century) illustrates a recurring pattern: empirical success can precede theoretical understanding by generations.

Question 2

The global eradication of smallpox, declared complete in 1980, was one of public health's greatest achievements. What made eradication possible for smallpox when it has not been achieved for most other diseases?

• A. Smallpox had a very long incubation period that made quarantine effective
• B. Smallpox had no animal reservoir, humans were the only host, and an effective vaccine existed — features that made elimination campaigns feasible
• C. A very effective antibiotic treatment was discovered that cured smallpox
• D. Smallpox was eradicated through natural evolutionary extinction, not human intervention

Answer: (B)

Smallpox eradication was feasible because of three features: (1) no animal reservoir — humans were the only host, so eliminating human cases would eliminate the disease; (2) an effective vaccine was available that conferred durable immunity; (3) smallpox was identifiable — it produced visible lesions, allowing surveillance and ring vaccination (vaccinating contacts of confirmed cases). The WHO campaign (1967-1980) used these features, focusing on surveillance and ring vaccination rather than mass vaccination of entire populations. Diseases with animal reservoirs (rabies, influenza) cannot be eradicated by eliminating human cases.

Question 3

What is 'herd immunity,' and at what vaccination coverage level is it typically achieved for measles?

Model answer: Herd immunity refers to indirect protection of unvaccinated individuals when enough of the population is immune: if a sufficient fraction of people cannot be infected, chains of transmission break and even vulnerable individuals (infants, immunocompromised people) are protected. The required coverage depends on a disease's basic reproduction number (R0 — how many people one infected person infects in a fully susceptible population). Measles has an R0 of 12-18, meaning one infected person infects 12-18 others on average. Herd immunity for measles requires approximately 92-95% vaccination coverage — among the highest of any vaccine-preventable disease.

The high R0 of measles means that small drops in vaccination coverage (even from 95% to 90%) can allow measles outbreaks in otherwise largely vaccinated populations. This is why measles outbreaks recur in communities with high but not quite sufficient vaccination rates.

Question 4

mRNA vaccines, like the COVID-19 vaccines developed in 2020, represent a fundamentally new vaccine platform. How do they differ from traditional vaccines?

Model answer: Traditional vaccines introduce either weakened (live-attenuated) pathogens, killed pathogens, or protein subunits from pathogens. The immune system responds to these antigens by producing antibodies and memory cells. mRNA vaccines instead deliver genetic instructions (mRNA) encoding a viral protein (for COVID-19, the spike protein). Cells read these instructions and produce the protein; the immune system responds to the protein. No viral genetic material enters the nucleus; the mRNA degrades quickly. This platform enables rapid vaccine design (once the viral genome is sequenced, mRNA can be synthesized within days) and avoids growing large quantities of pathogen.

mRNA vaccine technology had been in development for decades before COVID-19, but the pandemic provided the urgency and funding for rapid clinical development. The speed of COVID-19 vaccine development (less than a year) was possible because of this existing technological foundation.

Question 5

Vaccine skepticism and anti-vaccination movements have existed since Jenner's time. The modern anti-vaccine movement in wealthy countries is primarily driven by new scientific evidence against vaccine safety.

• T. True
• F. False

Answer: False

The modern vaccine hesitancy movement in wealthy countries is primarily driven not by new scientific evidence but by: (1) distrust of pharmaceutical companies and government health authorities; (2) a fraudulent 1998 Lancet paper by Andrew Wakefield claiming a link between MMR vaccine and autism (retracted in 2010, Wakefield struck off); (3) success of vaccines creating a paradox — once diseases are rare, risks of vaccines become more salient than risks of diseases; (4) social media amplifying anecdotal adverse event reports. Multiple large studies have found no link between vaccines and autism. The scientific consensus on vaccine safety is clear.